A typology-based decisional framework to support market access and reimbursement decisions for personalised medicines
dc.contributor.author | Govaerts, Laurenz | |
dc.contributor.author | Geldof, Tine | |
dc.contributor.author | Simoens, Steven | |
dc.contributor.author | Huys, Isabelle | |
dc.date.accessioned | 2018-01-23T14:37:23Z | |
dc.date.available | 2018-01-23T14:37:23Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 1098-3015 | |
dc.identifier.doi | 10.1016/j.jval.2017.08.1586 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12127/5898 | |
dc.description.abstract | New co-development approaches in personalized medicine challenge current decisional frameworks of health-technology access and reimbursement procedures. We aim to conceptualize an efficient typology-based decisional framework which takes into account the development and market access synchronism between therapeutic (Tx) and diagnostic (Dx) components of personalized medicines. | |
dc.language.iso | en | |
dc.publisher | Blackwell Pub. | |
dc.subject | Healthcare | |
dc.subject | Clinical Pharmacology | |
dc.subject | Pharmacotherapy | |
dc.title | A typology-based decisional framework to support market access and reimbursement decisions for personalised medicines | |
dc.identifier.journal | Value in Health. The Journal of the International Society for Pharmacoeconomics and Outcomes Research | |
dc.source.volume | 20 | |
dc.source.issue | 9 | |
dc.source.beginpage | A661 | |
dc.source.endpage | A661 | |
dc.contributor.department | KU Leuven | |
dc.identifier.eissn | 1524-4733 | |
vlerick.knowledgedomain | Special Industries : Healthcare Management | |
vlerick.typearticle | Journal article | |
vlerick.vlerickdepartment | TOM | |
dc.identifier.vperid | 176581 | |
dc.identifier.vperid | 31183 |